X-linked retinoschisis

X-linked retinoschisis (XLRS), also known as juvenile retinoschisis or congenital retinoschisis, is an inherited retinal dystrophy that primarily affects males. It is caused by pathogenic variants in the RS1 gene located on the X chromosome, which encodes retinoschisin, a protein essential for maintaining the structural integrity of the retina. The hallmark feature of the disease is splitting (schisis) of the retinal layers, most characteristically involving the fovea, the central part of the retina responsible for sharp, detailed vision. Foveal schisis, which appears as a spoke-wheel pattern on examination, is present in virtually all affected individuals and leads to reduced central visual acuity, typically in the range of 20/60 to 20/120. Beyond foveal involvement, approximately 50% of affected males also develop peripheral retinoschisis, which can predispose to complications such as vitreous hemorrhage and retinal detachment. Visual acuity tends to be relatively stable through early and middle adulthood but may progressively decline in later decades. Additional findings can include strabismus and hyperopia. Electroretinography (ERG) characteristically shows a reduced b-wave amplitude with a relatively preserved a-wave, reflecting inner retinal dysfunction. Optical coherence tomography (OCT) is a key diagnostic tool that reveals the characteristic cystic splitting of retinal layers at the fovea. Currently, there is no definitive cure for X-linked retinoschisis. Management is primarily supportive and includes regular ophthalmologic monitoring, correction of refractive errors, and treatment of complications such as retinal detachment or vitreous hemorrhage through surgical intervention when necessary. Carbonic anhydrase inhibitors (such as dorzolamide or acetazolamide) have been used in some patients to reduce foveal cystic changes, though results are variable. Gene therapy clinical trials targeting the RS1 gene are under investigation and represent a promising future therapeutic approach. Female carriers are typically unaffected or may show very mild subclinical retinal changes.

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Common questions about X-linked retinoschisis